Delving into the Latest Updates on Levocabastine Hydrochloride with Synapse

Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.

Start Date01 Jul 2019

Sponsor / Collaborator

Beijing Tongren Hospital Management Co., Ltd.

[+1]

KCT0004672 / CompletedNot ApplicableIIT

Double blind, randomized controlled study to evaluate the efficacy and safety of extract of leaves of Dendropanax morbiferous H. Lev on the glucose metabolism

Start Date23 Jul 2018

Sponsor / Collaborator-

JPRN-UMIN000017531 / RecruitingIIT

Evaluation of the effect of the antiepiletic levetiracetum on seizure control and expression of MGMT in patients with gliomas (Phase II clinical trial) - LEV for Glioma

Start Date06 Oct 2014

Sponsor / Collaborator-

100 Clinical Results associated with Levocabastine Hydrochloride

Login to view more data

100 Translational Medicine associated with Levocabastine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Levocabastine Hydrochloride

Login to view more data

298

Literatures (Medical) associated with Levocabastine Hydrochloride

01 Jul 2024·Journal of Pharmacological and Toxicological Methods

Evaluation methods using tear volume in a conjunctivitis mice model

Article

Author: Kai, Haruki ; Sugimoto, Yukio ; Haraoka, Noriaki

Allergic conjunctival disease is an immune-mediated inflammatory disease of the conjunctiva. To develop clinically useful drugs, it is necessary to develop quantitative evaluation methods that reflect the clinical symptoms in experimental animal models. Allergic conjunctivitis model mice were systemically sensitised with ovalbumin (OVA) administered intraperitoneally and locally sensitised with OVA eye drops between day 14-28. Next, conjunctivitis induced by ocular administration of OVA solution to sensitised mice was evaluated based on tear volume. Additionally, we evaluated increase in tear volume induced by direct ocular instillation of histamine, compound 48/80, and carrageenan. An increase in antigen-induced tear volume was observed in the mice model. Additionally, direct instillation of histamine, compound 48/80, and carrageenan increased tear volume. Furthermore, levocabastine inhibited the increase in tear volume in antigen-induced allergic conjunctivitis and histamine- and compound 48/80-induced conjunctivitis models. In contrast, betamethasone suppressed carrageenan-induced tear volume but not histamine- or compound 48/80-induced tear volume. Histamine may be involved in increased tear volume in allergic conjunctivitis. Betamethasone is not directly involved in the action of histamine and is thought to suppress increase in tear volume. Evaluation of tear volume in a conjunctivitis mice model is highly quantitative; therefore, it is possible to evaluate drug efficacy. This is considered a useful index compared with conventional methods.

23 Mar 2024·Journal of Biomolecular Structure and Dynamics

In-silico identification of novel DDI2 inhibitor in glioblastoma via repurposing FDA approved drugs using molecular docking and MD simulation study

Article

Author: Majumder, Ranabir ; Mandal, Mahitosh ; Roy, Pritam Kumar

Glioblastoma, the most severe form of brain tumor and a leading cause of death within a year of diagnosis, is characterized by excessive protein synthesis and folding in the lumen of the endoplasmic reticulum (ER), leading to increased ER stress in the cells of GBM tissues. To mitigate this stress the cancer cells have intelligently adopted a plethora of response mechanisms and Unfolded Protein Response (UPR) is one of those. To bear with this exhaustive situation cells upregulate a strong protein degradation system in form of 26S proteasome and blocking of proteasomal gene synthesis may be a potential therapeutic action against GBM. Proteasomal gene synthesis is exclusively dependent on the transcription factor Nuclear respiratory factor 1 (NRF1) and its activating enzyme DNA damage inducible 1 homolog 2 (DDI2). Here in this study, we performed molecular docking against DDI2 with the 20 FDA-approved drugs and identified Alvimopan and Levocabastine as the top two compounds with the best binding score along with the standard drug Nelfinavir. MD simulation (100 ns) of these protein-ligand docked complexes reveals that the stability and compactness of Alvimopan are high in comparison with Nelfinavir. Our in-silico (Molecular docking and Molecular dynamics simulation) studies pointed out that Alvimopan may be repurposed as a DDI2 inhibitor and can be used as a potential anticancer agent for the treatment of brain tumors.Communicated by Ramaswamy H. Sarma.

01 Feb 2024·Toxicology and Applied Pharmacology

Levocabastine ameliorates cyclophosphamide-induced cardiotoxicity in Swiss albino mice: Targeting TLR4/NF-κB/NLRP3 signaling pathway

Article

Author: Alam, M Mumtaz ; Najmi, Abul Kalam ; Akram, Wasim ; Haque, Syed Ehtaishamul

Cyclophosphamide (CP), although a potent anti-cancer drug, causes cardiotoxicity as a side effect that limits its use. Hence, a specific medicine that can lower cardiotoxicity and be utilised as an adjuvant in cancer treatment is very much needed. In this light, we intended to assess the protective potential of levocabastine (LEV) on CP-induced cardiotoxicity in Swiss albino mice. Mice were administered LEV (50 and 100 μg/kg, i.p.) daily for 14 days and CP at 200 mg/kg, intraperitoneally once on the 7th day. On the 15th day, mice were weighed, blood withdrawn then sacrificed and hearts were removed to estimate various biochemical and histopathological parameters. CP 200 mg/kg significantly increased cardiac troponin T, LDH, CK-MB, interleukin-1β, IL-6, TNF-α, TBARS, nitrite, and decreased CAT, GSH, and SOD levels, thus, manifested cardiac damage, inflammation, oxidative stress, and nitrative stress, cumulatively causing cardiotoxicity. CP also elevated the expression of various markers including cleaved caspase-3, NF-κB, TLR4, NLRP3, and fibrotic lesions in cardiac tissues, whereas decreased hematological parameters (RBCs, platelets, and Hb) to confirm cardiotoxicity. LEV and fenofibrate (FF) treatment reversed these changes towards normal and showed a significant protective effect against CP. The results showed the protective role of LEV in restoring CP-induced cardiotoxicity in terms of inflammation, apoptosis, oxidative stress, cardiac injury and histopathological damage. Thus, levocabastine can be used as an adjuvant to cyclophosphamide in cancer treatment but a thorough study with various animal cancer models is further needed to establish the fact.

100 Deals associated with Levocabastine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01717	Levocabastine Hydrochloride	R01AC02 S01GX02	DB01106

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rhinitis, Allergic, Seasonal	CN	Johnson & Johnson Consumer NV	24 Jul 2018
Conjunctivitis, Allergic	JP	Santen Pharmaceutical Co., Ltd.	22 Sep 2000
Conjunctivitis, Allergic	JP	Janssen Pharmaceutical KK	22 Sep 2000

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Perennial allergic rhinitis with seasonal variation	Discovery	CA	GSK Plc	01 Oct 2013
Perennial allergic rhinitis with seasonal variation	Discovery	AT	GSK Plc	01 Oct 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01949051 (CTgov)	Phase 2	Perennial allergic rhinitis with seasonal variation	78	placebo (Placebo)	pacxqzwmbv(ykwfucyhao) = pkjhgtlfsn wdojlkesyp (cxharezhdu, xjqrmaqdgk - kltvplpufv) View more	-	25 Sep 2014
				Levocabastine (Levocabastine 200µg OD)	pacxqzwmbv(ykwfucyhao) = zxccvcainf wdojlkesyp (cxharezhdu, fqucvoqnmi - jnzmtjvckq) View more
ARVO2007	Not Applicable	Conjunctival Diseases ICAM-1 \| VLA-4 \| VCAM-1	-	Levocabastine	wtjgzbnpcl(aalbhbyugn) = qabuyflqjv odrlspktin (bubhpygxuy )	-	01 May 2007
ARVO2003	Not Applicable	Seasonal allergic conjunctivitis	-	Epinastine HCl 0.05%	(mqldjocpnr) = dxmlfimbxm cmrjrelrjv (szmopfbatc )	Positive	01 May 2003
				Levocabastine 0.05%	(mqldjocpnr) = zgmlxwycve cmrjrelrjv (szmopfbatc )